Jupiter,

Very grateful for this breakdown--raises a lot of great questions for further analysis of current data as well as potential tailoring for possible future study.

I am very much interested in restraining judgement against the academics, FDA, etc. largely because that side of the equation is foreign to me (and I'm sure many investors on this hub, excluding those with significant experience in the sciences). However, it would be a lie to say that from an untrained eye, some of these results, for patients in dire need, appear to be so promising that it would be a shame not to start treating them with a very safe drug that appears to help them at a relatively low cost.  I understand if this view is scientifically uninformed, and it would be helpful to know this if true.

I would be grateful to you, or to anyone else that has more experience in this area, if you might profer what you think would be the appropriate path forward.  This would help to form realistic expectations, and perhaps temper the temptation toward viewing the possitives with rose colored (or money green) glasses.

Bottom line: is this drug ready to help people that need it (and produce profits)? Is it in need of more studies (from a wealthy BP)?  The potentail health and monetary beneficiaries would all love to know!